Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
about
Activation of human meprin-alpha in a cell culture model of colorectal cancer is triggered by the plasminogen-activating systemDrug development against metastasis-related genes and their pathways: A rationale for cancer therapyTumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy.Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients.Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.Prognostic role of urokinase plasminogen activator receptor in gastric and colorectal cancer: A systematic review and meta-analysis.A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogenInhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.Distinct ligand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact.Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2.Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.HMGA2 is a driver of tumor metastasis.Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells.Involvement of urokinase-type plasminogen activator system in cancer: an overview.Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor).Genome-controlled reverse transcriptase-polymerase chain reaction for targeted gene-expression analysis.Tumor Budding, uPA, and PAI-1 in Colorectal Cancer: Update of a Prospective Study.Stromal cell-derived factor-1/CXC receptor 4 and β1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells.Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis.Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells.In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells.Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.The role of Ly49E receptor expression on murine intraepithelial lymphocytes in intestinal cancer development and progression.[Expression and clinical relevance of uPA and ET-1 in non-small cell lung cancer].Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.Identification of a characteristic copy number alteration profile by high-resolution single nucleotide polymorphism arrays associated with metastatic sporadic colorectal cancer
P2860
Q28218647-BDE092B0-0800-4B96-8665-F4232E21EC1EQ29010479-6B336137-34D7-4C8F-A706-55BF536F370CQ33350682-20DBAB78-3970-47B1-9262-A2C9E107C9D3Q33867384-F657FA99-B3A6-4F59-9B75-CA90F9FBA2AAQ34165118-F3CBA8FF-1FB2-442F-9E3C-C67F66C818F5Q34733963-71FB4D02-CEFC-402C-B69D-61C8A9F9297AQ35097486-32E530E2-8A34-4602-BA24-767BD9437FBDQ35699282-F175E404-726F-43A2-B885-7B9A31B826C6Q35781008-2CA1103C-F289-4F22-BE73-986421DED28AQ36059078-37845010-33FC-493B-A44E-EF32EEFB5EEFQ36302249-2341200B-9377-46BC-B1C1-3C40606F63D1Q36324407-F79EC337-7399-4CD9-819B-2DAF9204E2C2Q36648790-EC6329C1-5205-43E4-8686-AAFC246C5AFDQ36666169-03D75210-0CBA-4231-A0E5-076BB6BF2E8EQ37025050-39231293-7404-4178-B11D-A563577811DEQ37233640-8740CBCA-0868-4E3D-9D2A-07C2628973EEQ38189275-E2170B9E-EDE2-48D9-A52C-320BC36DB053Q38331352-6C7AB318-52CC-40C7-88D5-5F635471CC83Q38435255-D3C9FFAC-C8F3-4FA5-893B-DBDE7681A02CQ38912093-1C959EAC-1F97-4818-8352-48509C9C456FQ39543648-ED4FEE18-4105-4A3B-9C91-1B8BC6498973Q40988377-08DFEC13-B610-476F-8772-704C7E5AD68EQ41460793-B6DBFC8C-BA4A-4F67-80B1-A6C056FA18FDQ43770510-7D285C3D-DAEC-42BA-9172-DEA666FA8896Q43907665-C3A42B35-DB27-4490-B7F1-4E63A112027AQ46906937-C7B630A6-3FB6-492E-9747-66BB947E643DQ48293366-53FE1DEA-AFB4-4A95-8A47-9816E60CBB3FQ51610334-C603FF2C-EA04-4D65-9AB6-B08506D58EFDQ54960825-0A7F1123-A643-4DFF-8B3E-A46EFC9B577CQ58051474-50748588-078F-4509-ADA5-2AEB554AE858
P2860
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Urokinase-type plasminogen act ...... potential therapeutic targets.
@en
type
label
Urokinase-type plasminogen act ...... potential therapeutic targets.
@en
prefLabel
Urokinase-type plasminogen act ...... potential therapeutic targets.
@en
P2093
P2860
P1476
Urokinase-type plasminogen act ...... potential therapeutic targets
@en
P2093
P2860
P304
P356
10.1002/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V
P577
2000-09-01T00:00:00Z